Utility of Autonomic Function Tests to Differentiate Dementia with Lewy Bodies and Parkinson Disease with Dementia from Alzheimer Disease

2017 ◽  
Vol 79 (1-2) ◽  
pp. 27-32 ◽  
Author(s):  
Shuta Toru ◽  
Tadashi Kanouchi ◽  
Takanori Yokota ◽  
Yosuke Yagi ◽  
Akira Machida ◽  
...  

Objective: We studied autonomic disturbance in patients with dementia with Lewy bodies (DLB), Parkinson disease with dementia (PDD), Alzheimer disease (AD), to determine whether autonomic function tests can be used to distinguish these disorders. Methods: Autonomic function was tested in 56 patients with DLB, 37 patients with PDD, and 59 patients with AD by using the sympathetic skin response, coefficient of variation in R-R interval, the head-up tilt test, serum norepinephrine concentration, and 123I-meta-iodobenzylguanidine cardiac scintigraphy. Symptoms of autonomic dysfunction, such as constipation, urinary symptoms, and orthostatic hypotension, were also noted. Results: The groups did not differ on baseline characteristics other than those associated with Parkinsonism and dementia. All patients with DLB and PDD had some dysautonomia, whereas rates were much lower for patients with AD (19%). Significantly more DLB and PDD patients than AD patients showed abnormalities on autonomic function tests. Conclusions: Autonomic function tests might be quite useful to distinguish DLB and PDD from AD.

2015 ◽  
Vol 23 (2) ◽  
pp. 141-148 ◽  
Author(s):  
David R. Whitfield ◽  
Julie Vallortigara ◽  
Amani Alghamdi ◽  
Tibor Hortobágyi ◽  
Clive Ballard ◽  
...  

2019 ◽  
Vol 34 (7-8) ◽  
pp. 421-432
Author(s):  
Ioannis Mavroudis ◽  
Foivos Petridis ◽  
Dimitrios Kazis

Dementia with Lewy bodies is a progressive neurodegenerative disorder, clinically characterized by gradual cognitive impairment and fluctuating cognition, behavioral changes and recurrent visual hallucinations, and autonomic function and movement symptoms in the type of parkinsonism. It is the second most common type of dementia in the Western world after Alzheimer disease. Over the last 20 years, many neurophysiological, neuroimaging, and cerebrospinal fluid (CSF) biomarkers have been described toward a better discrimination between dementia with Lewy bodies, Alzheimer disease, and other neurodegenerative conditions.In the present review, we aim to describe the neurophysiological, imaging, and CSF biomarkers in dementia with Lewy bodies and to question whether they could be reliable tools for the clinical practice.


Neurology ◽  
2008 ◽  
Vol 70 (4) ◽  
pp. 299-303 ◽  
Author(s):  
G. N. Ransmayr ◽  
S. Holliger ◽  
K. Schletterer ◽  
H. Heidler ◽  
M. Deibl ◽  
...  

2003 ◽  
Vol 16 (2) ◽  
pp. 85-92 ◽  
Author(s):  
Deborah A. Cahn-Weiner ◽  
Karren Williams ◽  
Janet Grace ◽  
Geoffrey Tremont ◽  
Holly Westervelt ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document